Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: